» Articles » PMID: 33693799

Sleep Disruption, Fatigue, and Depression As Predictors of 6-Year Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation

Overview
Specialty Oncology
Date 2021 Mar 11
PMID 33693799
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Allogeneic hematopoietic cell transplantation (HCT) is a widely used treatment for hematologic cancers, with survival rates ranging from 25% to 78%. Known risk factors for chronic graft-versus-host disease (cGVHD), a serious and common long-term complication, disease relapse, and mortality following HCT have been identified, but much of the variability in HCT outcomes is unexplained. Biobehavioral symptoms including depression, sleep disruption, and fatigue are some of the most prevalent and distressing for patients; yet research on biobehavioral risk factors for HCT outcomes is limited. This study evaluated patient-reported depression, sleep disruption, and fatigue as risk factors for cGVHD, disease relapse, and mortality.

Methods: Adults receiving allogeneic HCT for a hematologic malignancy (N = 241) completed self-report measures of depression symptoms, sleep quality, and fatigue (severity, interference) pre-HCT and 100 days post-HCT. Clinical outcomes were monitored for up to 6 years.

Results: Cox proportional hazard models (2-tailed) adjusting for patient demographic and medical characteristics revealed that high pre-HCT sleep disruption (Pittsburgh Sleep Quality Index >9; hazard ratio [HR] = 2.74, 95% confidence interval [CI] = 1.27 to 5.92) and greater post-HCT fatigue interference (HR = 1.32, 95% CI = 1.05 to 1.66) uniquely predicted increased risk of mortality. Moderate pre-HCT sleep disruption (Pittsburgh Sleep Quality Index 6-9) predicted increased risk of relapse (HR = 1.99, 95% CI = 1.02 to 3.87). Biobehavioral symptoms did not predict cGVHD incidence.

Conclusions: Biobehavioral symptoms, particularly sleep disruption and fatigue interference, predicted an increased risk for 6-year relapse and mortality after HCT. Because these symptoms are amenable to treatment, they offer specific targets for intervention to improve HCT outcomes.

Citing Articles

Biobehavioral mechanisms underlying symptoms in cancer patients with chronic graft-versus-host disease.

Hansen J, Rumble M, Coe C, Juckett M, Foster M, Dickson D Brain Behav Immun. 2024; 123:185-192.

PMID: 39288894 PMC: 11624090. DOI: 10.1016/j.bbi.2024.09.017.


Intervention effects of telenursing based on M-O-A model in empty-nest older adult individuals with chronic diseases: a randomized controlled trial.

Yuan Y, Hou P, Wang S, Kitayama A, Yanagihara K, Liang J Front Public Health. 2024; 12:1239445.

PMID: 38868161 PMC: 11168200. DOI: 10.3389/fpubh.2024.1239445.


eHealth mindfulness-based music therapy for patients undergoing allogeneic hematopoietic stem cell transplantation: A pilot randomized controlled trial protocol.

Fleszar-Pavlovic S, Esquives B, Brito A, Sia A, Kauffman M, Lopes M Contemp Clin Trials. 2024; 142:107577.

PMID: 38763308 PMC: 11244650. DOI: 10.1016/j.cct.2024.107577.


A prospective study of the relationship between illness perception, depression, anxiety, and quality of life in hematopoietic stem cell transplant patients.

Ames S, Lange L, Ames G, Heckman M, White L, Roy V Cancer Med. 2024; 13(3):e6906.

PMID: 38205943 PMC: 10905249. DOI: 10.1002/cam4.6906.


Associations of Germline Genetic Variants With Depression and Fatigue Among Hematologic Cancer Patients Treated With Allogeneic Hematopoietic Cell Transplantation.

Hoogland A, Gonzalez B, Park J, Small B, Sutton S, Pidala J Psychosom Med. 2023; 85(9):813-819.

PMID: 37678326 PMC: 10915106. DOI: 10.1097/PSY.0000000000001251.


References
1.
Danaher E, Ferrans C, Verlen E, Ravandi F, Van Besien K, Gelms J . Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant. Oncol Nurs Forum. 2006; 33(3):614-24. DOI: 10.1188/06.ONF.614-624. View

2.
Socie G, Stone J, Wingard J, Weisdorf D, Henslee-Downey P, Bredeson C . Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999; 341(1):14-21. DOI: 10.1056/NEJM199907013410103. View

3.
Nelson A, Coe C, Juckett M, Rumble M, Rathouz P, Hematti P . Sleep quality following hematopoietic stem cell transplantation: longitudinal trajectories and biobehavioral correlates. Bone Marrow Transplant. 2014; 49(11):1405-11. PMC: 4221490. DOI: 10.1038/bmt.2014.179. View

4.
Huang H, Lin S, Chuang L, Wang C, Sun M, Li H . Severe OSA associated with higher risk of mortality in stage III and IV lung cancer. J Clin Sleep Med. 2020; 16(7):1091-1098. PMC: 7954049. DOI: 10.5664/jcsm.8432. View

5.
Bower J, Ganz P, Irwin M, Kwan L, Breen E, Cole S . Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?. J Clin Oncol. 2011; 29(26):3517-22. PMC: 3179252. DOI: 10.1200/JCO.2011.36.1154. View